8-K: Niki BioSolutions Regains Nasdaq Minimum Bid Price Compliance

Niki BioSolutions, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing at $1.00 or greater for ten consecutive business days.

Summary

• Niki BioSolutions, Inc. (formerly Aptorum Group Limited) received notification from Nasdaq that it has regained compliance with the minimum bid price requirement.
• The company's common stock closing bid price was $1.00 or greater for ten consecutive business days, from July 21, 2026, to August 3, 2026.
• This compliance period was granted following a deficiency letter received on March 5, 2026, due to the stock price being below $1.00 for 30 consecutive business days.
• The compliance period was set to expire on September 1, 2026.
• This matter is now considered closed by Nasdaq.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating the company has successfully addressed a critical listing requirement.

Positives

• Regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• Achieved the required closing bid price for ten consecutive business days (July 21, 2026 August 3, 2026).
• Successfully addressed a critical listing requirement within the provided compliance period.
• The Nasdaq matter related to the bid price is now closed.

Negatives

• Previously received a deficiency letter from Nasdaq on March 5, 2026, due to the stock price falling below $1.00 for 30 consecutive business days.
• The company's stock price had been below the minimum listing requirement, posing a risk to its Nasdaq listing.

Risks

• The company was at risk of delisting from The Nasdaq Capital Market if it failed to regain compliance with the minimum bid price requirement within the 180-day compliance period.
• Future fluctuations in stock price could again lead to non-compliance with listing rules.

Future Outlook

The filing does not contain specific forward-looking statements regarding future financial performance, but regaining Nasdaq compliance is a prerequisite for continued trading and future business operations.

Management Comments

• The company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this matter is now closed.

Industry Context

StockSavvy.ai notes that maintaining compliance with exchange listing rules, particularly minimum bid price requirements, is a common challenge for smaller-cap companies. Successfully regaining compliance is crucial for investor confidence and continued access to public markets.

Stakeholder Impact

• Shareholders: Increased confidence in the company's continued listing on Nasdaq, reducing the immediate risk of delisting.
• Creditors: Stability in the company's public trading status can positively impact perceptions of financial stability.
• Employees: Assurance of continued operations and potential for future growth without the immediate threat of delisting.

Next Steps

• Continue to monitor stock price to maintain compliance with Nasdaq listing rules.
• Focus on core business operations and strategic initiatives.

Key Dates

Recommendation

The filing confirms the company has resolved a critical listing deficiency, which removes an immediate overhang on the stock. However, the underlying reasons for the low stock price (implied by the deficiency) may persist, warranting a 'hold' recommendation until further positive operational or financial developments are evident.

Keywords

Nasdaq compliance, minimum bid price, stock listing, deficiency letter, Niki BioSolutions, Aptorum Group